Riskpilot← Back to searchSign inGet full accessCLINXICA AS
ASActiveOrg 919908513Kjølberggata 29C, 0653 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 20170 employees
Revenue 2024
NOK 0
EBITDA margin
—
-2705% vs 2023
Equity ratio
-87.2%
Financial strength
Net profit 2024
NOK -39K
-10442% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -38K | -2705% |
| Net profit | NOK -39K | -10442% |
| Total assets | NOK 29K | -1% |
| Equity | NOK -26K | -288% |
| Employees | 0 | — |
Legal name
CLINXICA AS
Org number
919908513
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
16. november 2017
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Import og eksport av medisinske og estetiske produkter, samt tilknyttet virksomhet.
Address
Kjølberggata 29C, 0653 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −6 | 0 | 0 | −1 | −2 | −8 | −1 | −38 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −6 | 0 | 0 | −1 | −2 | −8 | −1 | −38 |
| Net financials | 0 | 0 | 0 | 0 | 0 | 1 | 1 | −1 |
| Profit before tax | −6 | 0 | 0 | −1 | −2 | −8 | −0 | −39 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −6 | 0 | 0 | −1 | −2 | −8 | −0 | −39 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 30 | 30 | 30 | 29 | 28 | 29 | 30 | 29 |
| Equity | 24 | 25 | 25 | 23 | 22 | 14 | 14 | −26 |
| Long-term debt | 6 | 6 | 6 | 6 | 6 | 7 | 16 | 18 |
| Short-term debt | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 37 |
| Total debt | 6 | 6 | 6 | 6 | 6 | 15 | 16 | 55 |
EBITDA margin
-3786300.0%
This company
15.8%
Market median
-23964024% vs market
20172024
Equity ratio
-87.2%
This company
38.2%
Market median
-328% vs market
20172024
Return on equity
-3921600.0%
This company
18.4%
Market median
-21313143% vs market
20172024
Net profit margin
-3921600.0%
This company
8.1%
Market median
-48414915% vs market
20172024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172024
Debt / equity
2.15×
This company
0.62×
Market median
-247% vs market
20172024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2017 | — | — | |
| Chairman | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Oslo Hus As | Company | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Oslo Hus As
CLINXICA AS Board members of CLINXICA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Satinder Vir Singh | Chairman | 0 companies |
| Jasskaram Vir Singh Randhawa | Chairman | 0 companies |